Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.27% is 92% below its 5-year average of 3.47%, near the low end of its 5-year range (0.00%–16.16%).
As of the fiscal period ended Tuesday, March 31, 2026. 48.75% below its 12-month average of 0.53%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-03-31): 0.27%.
DEBT TO ASSETS RATIO
0.27%
DEBT TO ASSETS RATIO AVG TTM
0.53%
DEBT TO ASSETS RATIO AVG 3Y
0.56%
DEBT TO ASSETS RATIO AVG 5Y
3.47%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-48.75%
CURRENT VS 3Y AVG
-52.31%
CURRENT VS 5Y AVG
-92.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+169.18%
vs the sector median at left
BGM Group Ltd.
Market Cap
$111.84M
Debt to Assets Ratio
0.27%
TTM Avg
0.53%
3Y Avg
0.56%
5Y Avg
3.47%
Market Cap
$111.58M
Debt to Assets Ratio
0.14%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.75M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.78M
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.71M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.76M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.20M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.66M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $111.84M | 0.27% | 0.53% | 0.56% | 3.47% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.58M | 0.14% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.75M | 0.65% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.78M | 0.64% | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $109.24M | 0.00% | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.71M | 0.00% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 0.00% | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.20M | 0.03% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 0.01% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.30M | 0.21% | N/A | N/A | N/A |
Debt/Assets
0.3%
Debt/Equity
0.00
Current Ratio
1.25
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 0.27% |
| 2025-09-30 | 0.45% |
| 2025-03-31 | 0.86% |
| 2024-09-30 | 0.00% |
| 2024-03-31 | 0.20% |
| 2023-09-30 | 1.13% |
| 2023-03-31 | 1.05% |
| 2022-09-30 | 2.74% |
| 2022-03-31 | 16.16% |
| 2021-09-30 | 10.66% |
| 2021-03-31 | 4.67% |
| 2020-09-30 | 15.76% |
| 2020-03-31 | 17.25% |
| 2019-09-30 | 13.90% |
| 2019-03-31 | 12.53% |
| 2018-09-30 | 12.66% |
